NIH could fund animal-human stem cell research

Caitlin Wilson | | Health Exec | Precision Medicine

Injecting human stem cells into animal embryos will no longer make researchers ineligible for National Institutes of Health Funding, the agency announced August 4.

According to the New York Times, this change in stem cell research is different from research injecting regular human cells into animals. Human stem cells can then develop into any type of cell, and mixing human and animal stem cells, able to fuse or grow in any manner the researchers choose, can conjure up uncomfortable images of human-other animal hybrids. For example, if a human stem cells then develops into a human brain cell inside of another animal, what does that mean?

On the other hand, the insights gained from such research could help physicians better understand tumors and make organ transplant discoveries. Those advances could make it useful and productive for the NIH to invest in such funding.

Check out the New York Times to see more about the logistics of lifting the ban, plus more arguments for and against the move. 

N.I.H. May Fund Human-Animal Stem Cell Research

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”